Core Viewpoint - A class action lawsuit has been filed against Fiserv, Inc. on behalf of investors who purchased shares during the specified class period, alleging that the company's financial guidance was misleading [1][3]. Group 1: Lawsuit Details - The lawsuit was initiated by Berger Montague PC for investors who bought Fiserv shares from July 23, 2025, to October 29, 2025 [1]. - Investors have until January 5, 2026, to seek appointment as lead plaintiff representative of the class [2]. - The complaint claims that Fiserv's July 2025 financial guidance was materially false, as the assumptions behind it were difficult to achieve [3]. Group 2: Financial Impact - Following the disclosure of the misleading guidance on October 29, 2025, Fiserv's stock price fell by $55.57 per share, representing a 44% decline [3].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, captioned Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv-11319 [3]. - Investors have until January 26, 2026, to request to be appointed to lead the case [3]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Alexandria Real Estate securities [3]. Group 2: Company Background - Alexandria Real Estate is a real estate investment trust focused on tenants in life science industries, including pharmaceutical and biotechnology companies [4]. Group 3: Financial Performance and Stock Impact - Alexandria Real Estate reported lower-than-expected results for Q3 2025, leading to a stock price drop of $14.93 per share, or over 19%, from $77.87 to $62.94 on October 27-28, 2025 [6]. - The company announced a real estate impairment charge of $323.9 million, with $206 million attributed to its Long Island City property, which was deemed not suitable for life science scaling [5][6]. - Additional impairment charges may be recognized in Q4 2025, ranging from $0 to $685 million [6].

Core Viewpoint - Integer Holdings Corporation has faced significant challenges, leading to a reduction in its sales guidance for 2025 and a negative outlook for 2026, which has resulted in a substantial decline in its stock price [2][3]. Financial Performance - On October 23, 2025, Integer reduced its full-year 2025 sales guidance to a range of $1.840 billion to $1.854 billion, which is below prior expectations [2]. - The company anticipates net sales growth of –2% to 2% and organic sales growth of 0% to 4% for 2026 [2]. Product Performance - Management indicated that sales of three new products, including two electrophysiology devices, are expected to decline in 2026 due to slower market adoption than forecasted [2]. - The Cardio & Vascular sales growth is expected to decelerate, primarily due to declines in the electrophysiology products, with this impact continuing into 2026 [2]. Stock Market Reaction - Following the announcement of the reduced sales guidance, Integer's stock price fell by $35.22 per share, or 32.3%, closing at $73.89 per share on October 23, 2025 [3]. Legal Proceedings - A class action lawsuit has been filed alleging that Integer made materially false and misleading statements regarding its business and operations during the class period from July 25, 2024, to October 22, 2025 [4]. - The lawsuit claims that Integer overstated its competitive position in the electrophysiology manufacturing market and mischaracterized its EP devices as long-term growth drivers [4].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc for allegedly misleading investors regarding the performance of its North America Fiber Cement segment during the specified Class Period [1][3]. Company Overview - James Hardie Industries plc is a global building materials company headquartered in Dublin, Ireland, and is recognized as the world's largest manufacturer of fiber cement products [2]. Allegations - The lawsuit claims that James Hardie misrepresented the strength of its core North America Fiber Cement segment, stating that demand was strong and inventory levels were normal, while being aware that distributors were destocking inventory by April and early May 2025 [3]. Stock Performance - Following the company's disclosure of a 12% decline in the North America Fiber Cement segment on August 19, 2025, which was attributed to "normalization of channel inventories," the stock price plummeted by over 34%, resulting in significant losses for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. and its senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, captioned Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv-11319 [3]. - Investors have until January 26, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Alexandria Real Estate is a real estate investment trust (REIT) focused on tenants in life science industries, including pharmaceutical and biotechnology companies [4]. Group 3: Financial Performance and Stock Impact - Alexandria Real Estate reported disappointing results for Q3 2025, leading to a stock price drop of $14.93 per share, or over 19%, from $77.87 to $62.94 on October 28, 2025 [6]. - The company announced a real estate impairment charge of $323.9 million, with $206 million attributed to its Long Island City property, which was deemed not suitable for life science scaling [5][6].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was expected to meet high demand [5]. - Contrary to these assurances, Inspire allegedly failed to adequately prepare clinicians and payors for the rollout, leading to significant delays in adoption and weak demand due to existing inventory of older devices [6]. Stock Performance and Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price fell by $42.04 per share, a decline of more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, titled Laborers' District Council and Contractors' Pension Fund of Ohio v. James Hardie Industries plc, et al., No. 1:25-cv-13018 [3]. - Investors have until December 23, 2025, to request to be appointed to lead the case, with claims asserted under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Company Background - James Hardie is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [4]. Group 3: Allegations of Fraud - During the relevant period, James Hardie claimed strong performance in its North American fiber cement segment, stating it was seeing "normal stock levels" and expected performance [5]. - The lawsuit alleges that the reported sales were due to inventory loading by channel partners, indicating fraudulent channel stuffing rather than genuine customer demand [5]. Group 4: Stock Performance - On August 19, 2025, James Hardie disclosed a 12% decline in North American fiber cement sales, attributed to destocking efforts by customers, which was first noted in April and May [6]. - Following this announcement, the stock price fell by $9.79 per share, a decline of over 34%, from $28.43 to $18.64 per share [6]. Group 5: Executive Changes - On November 17, 2025, it was announced that Rachel Wilson would step down from her role as CFO of James Hardie [7].

Core Viewpoint - A securities class action lawsuit has been filed against StubHub Holdings, Inc. for allegedly making false and misleading statements in its Offering Documents related to its September 2025 initial public offering [1][2]. Group 1: Allegations Against StubHub - The lawsuit claims that StubHub failed to disclose significant changes in the timing of payments to vendors, which adversely affected its free cash flow [2]. - It is alleged that these undisclosed changes resulted in materially misleading reports regarding StubHub's free cash flow for the trailing 12 months [2]. - The complaint asserts that the positive statements made by StubHub about its business operations and prospects were materially false and lacked a reasonable basis due to the undisclosed issues [2]. Group 2: Lead Plaintiff Process - Investors in StubHub have until January 23, 2026, to seek appointment as a lead plaintiff representative in the class action [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is a prominent U.S. law firm specializing in securities-fraud class actions and investor protection [4]. - The firm has a history of leading significant recoveries in securities litigation and has received multiple accolades for its work [4].

Core Points - A class action lawsuit has been filed against James Hardie Industries plc on behalf of investors who purchased its common stock and American Depositary Shares between May 20, 2025, and August 18, 2025 [1][2] - The lawsuit claims that James Hardie overstated demand in its North American Fiber Cement segment and minimized the impact of distributor destocking that had started months prior [3] - Following the company's report of a 12% decline in segment sales on August 19, 2025, its stock price fell by over 34%, leading to significant losses for investors [3] Company Overview - James Hardie is a global building materials company that specializes in fiber cement products and is headquartered in Dublin, Ireland [2] Legal Context - Investors who purchased James Hardie securities during the specified Class Period have until December 23, 2025, to seek appointment as lead plaintiff representatives [2]

Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - Investors have until January 2, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Maryland [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of CarMax investors [2]. Group 2: Company Performance and Stock Impact - CarMax reported disappointing financial results for Q2 FY 2026, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [5]. - The company's net income for Q2 was approximately $95.4 million, down from $132.8 million the previous year, attributed to a "pull forward" in demand due to U.S. tariffs [5]. - Following the financial report, CarMax's stock price dropped by $11.45 per share, or roughly 20%, from $57.05 on September 24, 2025, to $45.60 on September 25, 2025 [6]. - An unexpected CEO departure on November 6, 2025, and a weak preliminary Q3 outlook led to an additional stock drop of over 24% [6]. Group 3: Investigations and Concerns - The law firm Bleichmar Fonti & Auld LLP is investigating the circumstances surrounding the unexpected departure of CEO Bill Nash and whether CarMax adequately assessed its portfolio of car loans [4].